# Tevogen Inc.

**TVGN**

Nasdaq; healthcare; SIC 2836, Biological Products, (No Diagnostic Substances); CIK 0001860871


# None

**No letter**

4 of 13 inputs computable; 7 are required, with a score in every sleeve


| Scoreboard | |
|---|---|
| **Reliability** | 0.76 AUC<br>filers with under $12.5M assets; 95% interval 0.65 to 0.86; 63 events, 2020 to 2025 |
| **Peer failure rate** | 0.60% a year<br>Item 1.03 bankruptcies, same asset band, 2012 to 2025 |
| **Size band** | under $12.5M assets<br>total assets $4.4M |
| **Warnings** | late filer, thin data<br>not computable: dilution, short runway, degenerate inputs, distress, fortress balance sheet |
| **Inputs computable** | 4 of 13 |
| **Graded from** | filings received through Apr 30, 2026<br>204 days before the rescan; latest periodic filing 10-Q received Nov 16, 2026 |
| **Last close** | $5.96<br>2026-11-19; market equity $0; no price enters the letter |

**Share price, twelve months to the rescan**




*Split-adjusted close. Each lollipop is a rescan and carries the letter held then.*

**Letter at every rescan, 2012 to 2026**




*Sector percentile at each rescan, stronger toward the top; facts filed by each date only.*

## Business, in the company's words

*opening of Item 1 of the 10-K received Mar 31, 2026*

are a clinical-stage specialty immunotherapy company harnessing one of nature's most powerful immunological weapons, CD8+ cytotoxic T lymphocytes ("CTLs"), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders, with the aim of addressing the significant unmet needs of large patient populations. We believe that sustainability and commercial success in the forthcoming era of medicine will rely on ensuring patient accessibility through advanced science, innovative business models and engagement throughout various stages of the drug development and commercialization lifecycle.

## The thirteen inputs

*lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight*

| Input | Value | Peer median | Percentile, 0 to 100 | Pct | Peers | Period end |
|---|---|---|---|---|---|---|
| **Profitability, sleeve percentile 0.8** | | | | | | |
| Gross profitability | not computable | 32.8% | | | | |
| *one or more required annual facts are missing* | | | | | | |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | | |
|---|---|---|---|---|---|---|
| Return on invested capital | not computable | 9.6% | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Accruals ratio | (355.6%) | (6.7%) | | 0.8 | 756 | 2025-12-31 |
| Gross margin stability, five years | not computable | 2.8 pts | | | | |
| *five annual gross margins are required; found 0* | | | | | | |
| **Solvency, sleeve percentile 97.8** | | | | | | |
| Altman Z double-prime | (152.92) | 0.31 | | 97.4 | 705 | 2025-12-31 |
| Net debt to EBITDA | not computable | 1.82x | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Interest coverage | not computable | (3.61x) | | | | |
| *latest aligned inputs end 2024-12-31; latest annual assets end 2025-12-31* | | | | | | |
| Current ratio | 0.22x | 2.68x | | 98.1 | 781 | 2025-12-31 |
| **Growth and financing, sleeve percentile 99.8** | | | | | | |
| Revenue growth, three-year compound | not computable | 9.6% | | | | |
| *four annual observations are required; found 0* | | | | | | |
| Free cash flow growth, three-year compound | not computable | 11.1% | | | | |
| *four consecutive annual FCF observations are required; found 1* | | | | | | |
| Reinvestment rate | not computable | 33.9% | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Asset growth, three years | (76.9%) | 3.2% | | 99.8 | 663 | 2025-12-31 |
| Net share issuance, one year | not computable | 1.6% | | | | |
| *firm-wide XBRL shares cannot be assigned to one ticker class* | | | | | | |

## Warnings

*2 of 7 checks triggered; none of them enters the letter*

| Check | Measured |
|---|---|
| Late filer | found 1 NT 10-K/Q filings in the last eight quarters |
| Thin data | 4 of 13 grade factors are computable; minimum is 7 |

## What the price implies

*at the 2026-11-19 close; none of these enters the grade*

| Measure | Value | Peer median | Percentile |
|---|---|---|---|
| Twelve-month price change, skipping the latest month | (78.9%) | (1.7%) | 5 |
| Distance from 52-week high | (73.8%) | (31.7%) | 12 |
| EBIT to enterprise value | not computable | 0.5% | |
| Free cash flow yield | not computable | 0.6% | |
| Book value to price | not computable | 0.29 | |
| Sales to price | not computable | 0.37 | |
| Composite equity issuance, five years | not computable | 13.5% | |
| Relative strength against the sector, log excess return | (1.73) | (0.19) | 5 |
| Twelve-month failure probability, CHS model | not computable | 0.06% | |

## Diagnostics

*shown on every report; none enters the grade*

| Measure | Value |
|---|---|
| **Piotroski F-score None of 9, period end 2025-12-31** | |
| Return on assets above zero | fail |
| Operating cash flow above zero | fail |
| Return on assets improved | fail |
| Operating cash flow exceeds net income | pass |
| Long-term leverage fell | fail |
| Current ratio improved | fail |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | |
|---|---|
| No new shares issued | fail |
| Gross margin improved | fail |
| Asset turnover improved | fail |
| **Cash, filings, liquidity** | |
| Cash and equivalents | n/a |
| Operating cash flow, four quarters | n/a |
| Months of runway | not finite |
| Days since last periodic filing | 4 (10-Q received Nov 16, 2026) |
| Median daily dollar volume, 63 sessions | $21,876 |

## Sources

*every fact behind the inputs; each row links to its filing index on sec.gov*

| # | Concept | XBRL tag | Value | Period end | Received | Form | Accession |
|---|---|---|---|---|---|---|---|
| 1 | net income | us-gaap:NetIncomeLoss | -$26.3M | 2025-12-31 | 2026-03-31 | 10-K | 26-014326 |
| 2 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$12.3M | 2025-12-31 | 2026-03-31 | 10-K | 26-014326 |
| 3 | assets | us-gaap:Assets | $4.4M | 2025-12-31 | 2026-03-31 | 10-K | 26-014326 |
| 4 | assets | us-gaap:Assets | $3.5M | 2024-12-31 | 2026-03-31 | 10-K | 26-014326 |
| 5 | current assets | us-gaap:AssetsCurrent | $1.5M | 2025-12-31 | 2026-03-31 | 10-K | 26-014326 |
| 6 | current liabilities | us-gaap:LiabilitiesCurrent | $7.1M | 2025-12-31 | 2026-03-31 | 10-K | 26-014326 |
| 7 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | -$139.7M | 2025-12-31 | 2026-03-31 | 10-K | 26-014326 |
| 8 | operating income | us-gaap:OperatingIncomeLoss | -$26.1M | 2025-12-31 | 2026-03-31 | 10-K | 26-014326 |
| 9 | book equity | us-gaap:StockholdersEquity | -$8.2M | 2025-12-31 | 2026-03-31 | 10-K | 26-014326 |
| 10 | liabilities | us-gaap:Liabilities | $12.6M | 2025-12-31 | 2026-03-31 | 10-K | 26-014326 |
| 11 | operating income | us-gaap:OperatingIncomeLoss | -$53.6M | 2024-12-31 | 2026-03-31 | 10-K | 26-014326 |
| 12 | interest expense | us-gaap:InterestExpense | $184,037 | 2024-12-31 | 2025-04-02 | 10-K | 25-002426 |
| 13 | assets | us-gaap:Assets | $5.5M | 2023-12-31 | 2025-04-02 | 10-K | 25-002426 |
| 14 | assets | us-gaap:Assets | $357.1M | 2022-12-31 | 2024-04-29 | 10-K | 24-016796 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.